HRP20241150T1 - (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga - Google Patents

(n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga Download PDF

Info

Publication number
HRP20241150T1
HRP20241150T1 HRP20241150TT HRP20241150T HRP20241150T1 HR P20241150 T1 HRP20241150 T1 HR P20241150T1 HR P20241150T T HRP20241150T T HR P20241150TT HR P20241150 T HRP20241150 T HR P20241150T HR P20241150 T1 HRP20241150 T1 HR P20241150T1
Authority
HR
Croatia
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Application number
HRP20241150TT
Other languages
English (en)
Croatian (hr)
Inventor
Mallory Factor
Taylor FIELDS
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of HRP20241150T1 publication Critical patent/HRP20241150T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20241150TT 2019-03-02 2020-03-02 (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga HRP20241150T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962812987P 2019-03-02 2019-03-02
US201962842296P 2019-05-02 2019-05-02
US201962888894P 2019-08-19 2019-08-19
US201962895144P 2019-09-03 2019-09-03
EP20712029.6A EP3934637B1 (en) 2019-03-02 2020-03-02 (n-)acetyl-l-leucine for use in treating traumatic brain injury
PCT/IB2020/051767 WO2020178721A1 (en) 2019-03-02 2020-03-02 Leucine, acetyl leucine, and related analogs for treating disease

Publications (1)

Publication Number Publication Date
HRP20241150T1 true HRP20241150T1 (hr) 2024-11-22

Family

ID=69845470

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241150TT HRP20241150T1 (hr) 2019-03-02 2020-03-02 (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga

Country Status (25)

Country Link
US (1) US20220142959A1 (https=)
EP (2) EP4464378A3 (https=)
JP (2) JP7555346B2 (https=)
KR (2) KR102941068B1 (https=)
CN (2) CN119097618A (https=)
AU (2) AU2020231189B2 (https=)
BR (1) BR112021017203A2 (https=)
CA (1) CA3131948A1 (https=)
DK (1) DK3934637T3 (https=)
ES (1) ES2990183T3 (https=)
FI (1) FI3934637T3 (https=)
HR (1) HRP20241150T1 (https=)
HU (1) HUE068527T2 (https=)
IL (2) IL285870B2 (https=)
LT (1) LT3934637T (https=)
MA (1) MA55199B1 (https=)
MD (1) MD3934637T2 (https=)
MX (2) MX2021010568A (https=)
PL (1) PL3934637T3 (https=)
PT (1) PT3934637T (https=)
RS (1) RS65849B1 (https=)
SG (1) SG11202109512SA (https=)
SI (1) SI3934637T1 (https=)
SM (1) SMT202400334T1 (https=)
WO (1) WO2020178721A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) * 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル-ロイシンの重水素化類似体
US20250025442A1 (en) * 2020-12-10 2025-01-23 Texas Tech University System BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
WO2025166100A1 (en) * 2024-02-02 2025-08-07 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
US20140080885A1 (en) * 2012-09-13 2014-03-20 University Of South Florida (A Florida Non-Profit Corporation) Methods of treating traumatic brain injury
US10905670B2 (en) * 2016-04-19 2021-02-02 Intrabio Ltd. Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2018029658A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
NZ750391A (en) 2016-08-11 2026-03-27 Intrabio Ltd Pharmaceutical compositions and uses directed to lysosomal storage disorders
WO2019036442A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY

Also Published As

Publication number Publication date
SG11202109512SA (en) 2021-09-29
ES2990183T3 (es) 2024-11-29
CN114040757A (zh) 2022-02-11
IL285870B2 (en) 2025-12-01
MA55199A (fr) 2022-01-12
SMT202400334T1 (it) 2024-09-16
IL321899A (en) 2025-09-01
CA3131948A1 (en) 2020-09-10
US20220142959A1 (en) 2022-05-12
IL285870B1 (en) 2025-08-01
EP3934637A1 (en) 2022-01-12
RS65849B1 (sr) 2024-09-30
LT3934637T (lt) 2024-08-26
BR112021017203A2 (pt) 2021-12-14
JP2024170602A (ja) 2024-12-10
EP4464378A3 (en) 2025-04-09
MD3934637T2 (ro) 2024-12-31
KR102941068B1 (ko) 2026-03-18
JP2022522819A (ja) 2022-04-20
AU2020231189A1 (en) 2021-09-30
MX2024015063A (es) 2025-01-09
EP3934637B1 (en) 2024-07-31
PT3934637T (pt) 2024-08-30
JP7555346B2 (ja) 2024-09-24
MX2021010568A (es) 2021-11-12
AU2025204995A1 (en) 2025-07-17
WO2020178721A1 (en) 2020-09-10
PL3934637T3 (pl) 2024-10-14
AU2020231189B2 (en) 2025-07-24
FI3934637T3 (fi) 2024-09-02
DK3934637T3 (da) 2024-09-02
CN119097618A (zh) 2024-12-10
KR20250171484A (ko) 2025-12-08
SI3934637T1 (sl) 2024-10-30
IL285870A (en) 2021-10-31
CN114040757B (zh) 2024-09-20
KR20210135272A (ko) 2021-11-12
MA55199B1 (fr) 2024-08-30
HUE068527T2 (hu) 2025-01-28
EP4464378A2 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
HRP20241150T1 (hr) (n-)acetil-l-leucin za uporabu u liječenju traumatske ozljede mozga
MX2024010140A (es) Nuevos metodos.
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
ME02395B (me) Kombinovana terapija sa antitumorskim alkaloidima
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
WO2018089328A8 (en) TREATMENT OF CNS DISEASES USING GCS STIMULATORS
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
WO2015187542A8 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
JP2015528501A5 (https=)
HRP20241552T1 (hr) Acetil-leucin ili njegova farmaceutski prihvatljiva sol za poboljšanu pokretljivost
JP2014526548A5 (https=)
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
EP4427738A3 (en) Dosing protocols and regimens for aminosterol treatment
HRP20191710T1 (hr) Postupci za liječenje poremećaja ciklusa uree
JPWO2020178721A5 (https=)
RU2016116955A (ru) Гидробромидная соль n-(4-хлор-2-гидрокси-3-((3s)-3-пиперидинилсульфонил)фенил)-n'-(3-фтор-2-метилфенил)мочевины
RU2016107197A (ru) Охлаждающе-согревающий пластырь
RU2021128588A (ru) Лейцин, ацетиллейцин и родственные аналоги для лечения заболевания